Other ASCO 2018 Highlights – It’s Not All IO

The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET. 

Digital illustration of Cancer cell in colour background

While the American Society of Clinical Oncology (ASCO) annual meeting, to be held June 1-5 in Chicago, has a long lineup of immune-oncology hits and misses, there’s plenty to stay on top of outside of immunotherapy, as shown by the ASCO preview report from Pharma Intelligence’s Pharma Biomedtracker and Datamonitor Healthcare analysts.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D